Twist Bioscience (NASDAQ:TWST) Stock: Insider Paula Green Sells 1,007 Shares

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 1,007 shares of the stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $135.40, for a total value of $136,347.80. Following the transaction, the senior vice president owned 105,625 shares in the company, valued at $14,301,625. This represents a 0.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Paula Green also recently made the following trade(s):

• On Friday, October 2nd, Paula Green sold 10,088 shares of Twist Bioscience stock. The shares were sold at an average price of $188.88, for a total value of $1,905,421.44.
• On Monday, September 21st, Paula Green sold 294 shares of Twist Bioscience stock. The shares were sold at an average price of $165.49, for a total value of $48,654.06.

Twist Bioscience Price Performance

Shares of TWST stock traded down $22.05 during trading hours on Thursday, hitting $120.53. 3,084,289 shares of the company’s stock were exchanged, compared to its average volume of 1,763,809. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. The firm has a market cap of $7.56 billion, a P/E ratio of -54.29 and a beta of 2.25. The firm has a 50 day moving average of $152.59 and a two-hundred day moving average of $90.28. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $219.71.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The business had revenue of $118.38 million for the quarter, compared to analysts’ expectations of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The company’s quarterly revenue was up 23.2% on a year-over-year basis. During the same quarter last year, the business earned $0.33 EPS. Sell-side analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Institutional Investors Weigh In On Twist Bioscience

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new stake in shares of Twist Bioscience in the 2nd quarter valued at approximately $600,191,000. William Blair Investment Management LLC purchased a new stake in shares of Twist Bioscience during the 2nd quarter valued at approximately $223,722,000. Bank of America Corp DE purchased a new stake in shares of Twist Bioscience during the 2nd quarter valued at approximately $94,922,000. Allspring Global Investments Holdings LLC purchased a new stake in shares of Twist Bioscience during the 1st quarter valued at approximately $22,563,000. Finally, Bank of New York Mellon Corp acquired a new position in Twist Bioscience in the second quarter valued at approximately $19,722,000.

Analyst Ratings Changes

TWST has been the topic of several research analyst reports. Barclays lifted their target price on shares of Twist Bioscience from $112.00 to $215.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. TD Cowen upped their price target on shares of Twist Bioscience from $115.00 to $190.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. Jefferies Financial Group assumed coverage on shares of Twist Bioscience in a research note on Thursday, October 8th. They issued a “hold” rating and a $150.00 price target on the stock. Piper Sandler lifted their price objective on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, August 5th. Finally, UBS Group assumed coverage on Twist Bioscience in a research note on Wednesday, September 9th. They set a “neutral” rating and a $144.00 price objective for the company. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $153.00.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.